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BACKGROUND: Heart failure, which is a major global health problem, is 
often preceded by pathological cardiac hypertrophy. The expansion of the 
cardiac vasculature, to maintain adequate supply of oxygen and nutrients, is a 
key determinant of whether the heart grows in a physiological compensated 
manner or a pathological decompensated manner. Bidirectional endothelial cell 
(EC)–cardiomyocyte (CMC) cross talk via cardiokine and angiocrine signaling 
plays an essential role in the regulation of cardiac growth and homeostasis. 
Currently, the mechanisms involved in the EC-CMC interaction are not fully 
understood, and very little is known about the EC-derived signals involved. 
Understanding how an excess of angiogenesis induces cardiac hypertrophy and 
how ECs regulate CMC homeostasis could provide novel therapeutic targets for 
heart failure.
METHODS: Genetic mouse models were used to delete vascular endothelial 
growth factor (VEGF) receptors, adeno-associated viral vectors to transduce the 
myocardium, and pharmacological inhibitors to block VEGF and ErbB signaling in 
vivo. Cell culture experiments were used for mechanistic studies, and quantitative 
polymerase chain reaction, microarrays, ELISA, and immunohistochemistry were 
used to analyze the cardiac phenotypes.
RESULTS: Both EC deletion of VEGF receptor (VEGFR)-1 and adeno-associated 
viral vector–mediated delivery of the VEGFR1-specific ligands VEGF-B or 
placental growth factor into the myocardium increased the coronary vasculature 
and induced CMC hypertrophy in adult mice. The resulting cardiac hypertrophy 
was physiological, as indicated by preserved cardiac function and exercise 
capacity and lack of pathological gene activation. These changes were mediated 
by increased VEGF signaling via endothelial VEGFR2, because the effects of 
VEGF-B and placental growth factor on both angiogenesis and CMC growth 
were fully inhibited by treatment with antibodies blocking VEGFR2 or by 
endothelial deletion of VEGFR2. To identify activated pathways downstream 
of VEGFR2, whole-genome transcriptomics and secretome analyses were 
performed, and the Notch and ErbB pathways were shown to be involved 
in transducing signals for EC-CMC cross talk in response to angiogenesis. 
Pharmacological or genetic blocking of ErbB signaling also inhibited part of the 
VEGF-B–induced effects in the heart.
CONCLUSIONS: This study reveals that cross talk between the EC VEGFR2 and 
CMC ErbB signaling pathways coordinates CMC hypertrophy with angiogenesis, 
contributing to physiological cardiac growth.
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Heart failure is a major worldwide health problem with an increasing socioeconomic burden. De-spite advances in heart failure treatment options, 
there is an urgent need for new therapies that impact 
not only the symptoms of the disease but also the un-
derlying pathological processes. Cardiac hypertrophy 
is an adaptive response of cardiomyocytes (CMCs) to 
physiological stimuli or pathological stress. Pathologi-
cal hypertrophy occurs in response to sustained cardiac 
overload (eg, hypertension or aortic stenosis) or after 
myocardial infarction, and it is often accompanied by 
increased fibrosis and heart failure.1 Physiological hy-
pertrophy develops in response to regular exercise 
training or during pregnancy, and it is reversible, unlike 
pathological cardiac remodeling.2 Thus, a mechanistic 
understanding of the molecular events that determine 
whether the heart grows in a physiological or patho-
logical manner could lead to the development of new 
therapeutic options for the treatment of heart failure.
The physiological growth of the myocardium re-
quires that myocyte growth be matched by a corre-
sponding expansion of the cardiac vasculature to main-
tain an adequate supply of oxygen and nutrients to the 
heart.3 In exercise-induced physiological hypertrophy, 
the heart preserves its oxygen supply by matching the 
proportional increases in CMC size and the extent of 
coronary microvasculature.4,5 In heart failure, however, 
pathological progression is associated with a mismatch 
between oxygen supply and demand, because the ex-
tent of CMC hypertrophy is associated with vascular 
rarefaction.6 Both heart size and cardiac function are 
angiogenesis dependent, and disruption of the coor-
dinated tissue growth and angiogenesis in the heart 
contributes to progression from adaptive cardiac hyper-
trophy to heart failure.7 Furthermore, the stimulation 
of vascular growth has been shown to increase cardiac 
mass in mice and rats,8–10 but the signaling mecha-
nisms that mediate this growth regulation are largely 
unknown. Endothelial cells (ECs) are the most abun-
dant cell type in the heart in terms of absolute num-
bers,11 although CMCs are predominant contributors to 
heart mass. Although ECs are increasingly recognized 
as regulators of tissue homeostasis and function, there 
are significant phenotypic differences between ECs in 
different tissues, and their importance in the heart has 
been underappreciated.12
Emerging evidence suggests that perturbed cross talk 
between CMCs and ECs is involved in the pathogenesis 
of several heart diseases,13 but the mechanisms of how 
the ECs affect CMC function are not well understood. 
In other tissues, such as in adult liver and lung, ECs and 
EC-derived secreted proteins, referred to as angiocrine 
factors, have been shown to control tissue growth and 
regeneration.14–16 In the heart, nitric oxide (NO), en-
dothelin-1, neuregulin (Nrg)-1, and apelin, which are 
produced by ECs, have been shown to regulate the 
functions of neighboring CMCs.13,17,18 However, the 
mechanisms that link angiogenesis and myocyte hyper-
trophy during cardiac growth have not been elucidated. 
Our previous studies have shown that an excess of vas-
cular endothelial growth factor B (VEGF-B) expression 
in the heart leads to increased coronary vasculature and 
mild cardiac hypertrophy.10,19
Members of the vascular endothelial growth factor 
(VEGF) family, including VEGF, VEGF-B, VEGF-C, VEGF-
D, and placental growth factor (PlGF), show distinct 
patterns of binding to VEGF receptors (VEGFRs) on ECs 
to differentially regulate blood and lymphatic vessel 
development and growth.20 VEGF-VEGFR2 signaling is 
essential for vascular development and maintenance, 
whereas VEGFR1 acts an antiangiogenic decoy receptor 
for VEGF and is required for proper vasculature devel-
opment.21–23 Here we show that indirect activation of 
VEGFR2 signaling in cardiac ECs induces angiogenesis 
and angiocrine release of ErbB receptor ligands. In turn, 
these ligands activate growth signaling in CMCs. No-
tably, the hypertrophy induced by angiogenic stimuli is 
reversible and does not progress to heart failure, thus 
resembling physiological cardiac growth. These findings 
place VEGFR2-ErbB signaling at the nexus of pathologi-
cal and physiological cardiac growth.
METHODS
Please refer to the online-only Data Supplement for an 
expanded Methods section. The data, analytical methods, 
and most of the study materials will be available to other 
researchers for purposes of reproducing the results or repli-
cating procedures by contacting the corresponding authors. 
Clinical Perspective
What Is New?
• We show that angiogenesis induces physiological 
cardiomyocyte hypertrophy via paracrine signaling 
between endothelial cells and cardiomyocytes.
• We demonstrate that the endothelial cell vascular 
endothelial growth factor receptor 2-Notch and 
cardiomyocyte ErbB signaling pathways coordinate 
cardiac hypertrophy and angiogenesis during phys-
iological myocardial growth.
What Are the Clinical Implications?
• There are several ongoing studies examining the 
utility of exogenous ErbB ligands for the treatment 
of cardiac diseases. Conversely, ErbB inhibitors are 
widely used in cancer treatment, which has been 
associated with cardiotoxicity.
• Our study highlights the importance of vascular 
endothelial growth factor receptor and ErbB signal-
ing in determining whether cardiac growth is physi-
ological or pathological.
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Some of the transgenic mouse lines were produced by 
other researchers and used under the restrictions of mate-
rial transfer agreements.
Mouse Models
All animal experiments were approved by the animal care 
committee appointed by the District of Southern Finland. All 
mouse lines and their backgrounds are listed in the online-
only Data Supplement. The animal numbers for each experi-
ment are provided in the respective figure legends.
Adeno-Associated Viral Vectors
Recombinant adeno-associated viral vectors (AAV; sero-
type 9) encoding mouse VEGFB186 (mVEGFB186), mouse 
PlGF (mPlGF), mouse VEGF164 (mVEGF164), or scrambled 
control sequences (Ctrl) were constructed and amplified as 
described previously.24
Blocking VEGFR2 and ErbB Signaling
To block VEGF/VEGFR2 signaling, 8-week-old C57BL/6J wild-
type (WT) mice were injected with AAV-Ctrl, AAV-mVEGFB186, 
or AAV-mPlGF and treated with DC101 monoclonal antibody 
(30 µg/g, Bio X Cell) every 3 to 4 days. To study the effects of 
ErbB signaling inhibition on VEGF-B–induced cardiac hyper-
trophy, recombinant AAV9-mErbB4ECD or AAV9-Ctrl was 
injected together with AAV9-mVEGFB186 into WT C57BL/6J 
mice. In addition, another group of mice were treated with 25 
mg/kg afatinib dimaleate (BIBW2992, catalog number S7810; 
Selleckchem) by oral gavage for 2 weeks.
Cell Culture
Human cardiac arterial ECs, human cardiac microvascular ECs, 
human dermal microvascular ECs, and human umbilical vein 
ECs were treated with recombinant VEGF (100 ng/mL) or PBS 
for 4 hours, and RNA was collected after stimulation. In another 
experiment, human cardiac microvascular ECs were cultured 
with serum-free medium overnight, then treated with VEGF165 
(50 ng/mL) for 1, 3, or 6 hours. Culture media were collected 
and subjected to ELISA analysis of Nrg1-β1 concentration.
Real-Time Quantitative Polymerase Chain 
Reaction, Immunohistochemical Staining 
of the Heart, ELISA, and Western Blotting
For the quantitative polymerase chain reaction, complete 
primer sequences and TaqMan probe set catalog numbers are 
listed in Tables I and II in the online-only Data Supplement. 
Antibodies and procedures used in immunohistochemistry, 
ELISA, and Western blotting are listed in Table III in the online-
only Data Supplement.
Microarray Analyses
The quality of RNA was determined with the Bioanalyzer sys-
tem (Agilent Technologies) and analyzed on genome-wide 
Illumina Mouse WG-6 v2 Expression BeadChips (Illumina). 
The microarray data have been submitted to the Gene 
Expression Omnibus database, under series accession num-
ber GSE110532.
Statistical Analysis
The data sets from individual experiments were analyzed 
by 2-way ANOVA with Holm-Sidak post hoc test or 2-tailed 
Student t test. P<0.05 was considered statistically significant. 
The data are presented as mean±SEM. GraphPad Prism 7 
software was used for these statistical analyses.
RESULTS
VEGFR1 Deletion From ECs Induces 
Angiogenesis and CMC Hypertrophy
We and others have shown that overexpression of 
VEGF-B or PlGF in the heart expands the coronary 
vasculature and induces CMC hypertrophy.9,10,19,25 To 
test whether VEGFR1 contributes to this process, we 
first studied the effects of VEGF-B in VEGFR1-TK−/− 
mice, which lack the tyrosine kinase (TK) domain of 
the VEGFR1, thus rendering the receptor unable to 
signal. Although cardiac vascular density and CMC 
size were higher in TK−/− knockout mice than in WT 
control mice, both were significantly increased after 
AAV-mediated delivery of VEGF-B (Figure IA through 
ID in the online-only Data Supplement), which indi-
cates that VEGFR1 TK activity is not required for the 
effects of VEGF-B in the heart.
We then deleted VEGFR1, the receptor for VEGF, 
VEGF-B, and PlGF, specifically from ECs by administering 
tamoxifen to 7- to 8-week-old Pdgfb-CreERT2;VEGFR1fl/fl 
mice (referred to as R1EC∆/∆ mice). This led to an ≈80% 
decrease in VEGFR1 mRNA and protein in the heart, as 
well as reduced levels of soluble extracellular domain of 
VEGFR1 in serum (Figure IIF through IIH in the online-
only Data Supplement). Considering the EC specificity 
of the VEGFR1 deletion (Figure IIA through IIC in the 
online-only Data Supplement), much of the remaining 
VEGFR1 mRNA and protein was attributed to non-EC 
cell types, such as macrophages.21 We then adminis-
tered AAV-VEGF-B to both WT and VEGFR1-deleted 
mice. The WT mice that received AAV-VEGF-B displayed 
increased coronary vasculature density and cardiac hy-
pertrophy (Figure 1A through 1F), as previously report-
ed.10 EC deletion of VEGFR1 also resulted in vascular 
and cardiac growth, and the combination of VEGFR1 
deletion and AAV-VEGF-B administration further en-
hanced both (Figure 1A through 1F), without any ef-
fect on overall body weight (Figure IID in the online-
only Data Supplement). VEGFR2 protein was increased 
in cardiac tissues of the VEGF-B transduced, VEGFR1 
deleted, and VEGFR1 TK−/− mice (Figure 1G; Figure IE 
through IG in the online-only Data Supplement). VEGF-
B overexpressing hearts also showed increased VEGFR2 
phosphorylation (Figure 1H and 1I) but no increase in 
VEGF mRNA (Figure IIE in the online-only Data Supple-
ment). Furthermore, silencing of VEGFR1 in cultured 
mouse ECs resulted in a significant increase of VEGFR2 
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Figure 1. VEGFR1 deletion from endothelial cells induces angiogenesis and cardiomyocyte hypertrophy.  
A, Representative images of staining for cardiomyocytes (Laminin-1), blood vessels (VEGFR2), and arteries (α-SMA) in AAV-VEGFB186–treated or VEGFR1-deleted 
hearts (R1EC∆/∆). B and C, Quantification of heart weight normalized to body weight and cardiomyocyte size (in µm2). (Continued )
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mRNA, which suggests an EC-intrinsic response (Figure 
IH in the online-only Data Supplement).
To compare the effects of VEGF-B overexpression 
and VEGFR1 deletion in the heart, we performed tran-
scriptomic profiling. AAV-VEGF-B expression, VEGFR1 
deletion, or their combination induced significant 
changes (false discovery rate <0.05) in 497, 212, and 
1499 transcripts, respectively. Of the genes upregulated 
in the VEGFR1-deleted hearts, 73% were also upregu-
lated in the VEGF-B–overexpressing hearts, and 39% 
of the genes downregulated by VEGFR1 deletion were 
also found to be decreased by VEGF-B overexpression 
(Figure  2A). These data suggest that VEGF-B over-
expression and endothelial VEGFR1 deletion control 
similar sets of gene-regulatory pathways to induce vas-
cular growth and cardiac hypertrophy. The transcripts 
increased in both included Notch ligands (Dll4, Jag1) 
and receptors (Notch1, Notch4), as well as apelin and 
Figure 1 Continued. D through F, Quantification of blood vessel area, average capillary size (in µm2), and α-SMA area. G, VEGFR2 protein concentration (in 
ng/mg) in the heart. H, Western blots of total VEGFR2 and phosphorylated VEGFR2 in VEGF-B–overexpressing and wild-type hearts. Heat shock cognate 70 
(HSC70) was used as a loading control. I, Quantification of the Western blot signals is shown as fold change compared with AAV-Ctrl treatment. Data are 
mean±SEM. AAV9 indicates adeno-associated viral vector serotype 9; CMC, cardiomyocyte; Ctrl, control; HW/BW, heart weight/body weight; mB186, mouse 
VEGF B-186; pVEGFR2, phosphorylated VEGFR2; α-SMA, α-smooth muscle actin; VEGF-B, vascular endothelial growth factor B; VEGFR2, vascular endo-
thelial growth factor receptor 2; and WT, wild type. Two-way ANOVA (Holm-Sidak test) and Student t test were used, as appropriate; *P<0.05, **P<0.01, 
***P<0.001 (N=4 per group). Scale bar, 100 µm.
Figure 2. Transcriptomic profiling of VEGFR1-deleted or AAV9-VEGFB186–overexpressing adult mouse heart.  
A, Venn diagram showing the number of common and unique cardiac gene expression changes in hearts deleted of VEGFR1 (R1EC∆/∆) or expressing AAV-VEGFB186 
or both, compared with control (WT+AAV9-Ctrl) mice. B, Validation of microarray findings for Notch signaling pathway genes and genes identified by secretome 
analysis in an independent experiment (normalized to Hprt-1). Data are mean±SEM. AAV9 indicates adeno-associated viral vector serotype 9; Ctrl, control; mB186, 
mouse VEGF B-186; VEGFR2, vascular endothelial growth factor receptor 2; and WT, wild type. Two-way ANOVA with Holm-Sidak multiple comparison test; 
*P<0.05, **P<0.01, ***P<0.001 (N=4 per group).
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APJ, which are recognized to be important for vascular 
or CMC growth. Stanniocalcin-1 and Esm-1 were the 
most upregulated genes in all 3 experimental condi-
tions. These results were corroborated by quantitative 
polymerase chain reaction analysis of samples from an 
independent experiment (Figure 2B).
To test whether the effect on cardiac growth was 
specific for VEGF-B, we administered AAV9-mPlGF2, 
encoding another VEGFR1 ligand, to WT and R1EC∆/∆ 
mice. PlGF induced cardiac hypertrophy in adult mice to 
a similar extent as VEGF-B (Figure III in the online-only 
Data Supplement), consistent with previous reports on 
transgenic mice.9,25 The mice expressing VEGF-B or PlGF 
displayed no overt health problems, unlike mice treated 
with a 5-fold lower dose of VEGF.22 We did not observe 
a significant increase in vascular leakage in various tis-
sues after VEGF-B treatment or VEGFR1 deletion, al-
though their combination resulted in slightly increased 
leakage which, however, was significantly less than 
that induced by VEGF (Figure IV in the online-only Data 
Supplement). Together, these findings indicate that the 
cardiac effects of VEGFR1 deletion from ECs and the 
overexpression of a VEGFR1 ligand are similar, in agree-
ment with the concept that VEGFR1 acts as an antian-
giogenic decoy receptor.22,23
VEGFR2 Signaling Mediates 
Angiogenesis-Induced CMC Hypertrophy
Deletion of VEGFR1 or an excess of VEGF-B or PlGF is 
expected to displace VEGF from VEGFR1 and increase 
endogenous free VEGF, allowing it to bind to and acti-
vate the main angiogenic signaling receptor, VEGFR2.21 
To determine whether activation of VEGFR2 was re-
sponsible for cardiac hypertrophy in AAV-VEGF-B–treat-
ed mice, we first blocked VEGF/VEGFR2 signaling using 
the anti-VEGFR2 antibody DC101. Strikingly, DC101 
treatment, when started concomitantly with the AAV 
transduction, completely inhibited the VEGF-B–induced 
cardiac hypertrophy, without affecting VEGF or VEGF-
B expression levels (Figure  3A and 3B and Figure VA 
and VB in the online-only Data Supplement). Next, we 
assessed whether the VEGF-B–induced cardiac hyper-
trophy could be reversed by VEGFR2 inhibition. In this 
experiment, DC101 treatment was started 2 weeks 
after the AAV injection, when significant hypertrophy 
was already observed in the VEGF-B–treated mice (Fig-
ure 3C). Both the expansion of the coronary vascula-
ture and CMC hypertrophy were completely reversed 
by DC101, which indicates that angiogenesis-induced 
cardiac hypertrophy is reversible and mediated by VEG-
FR2 signaling (Figure 3C through 3F and Figure VC and 
VD in the online-only Data Supplement). The VEGF-B–
induced increase in the mRNAs encoding Pecam1, VEG-
FRs, APJ, Esm1, and Stc1 (Figure 3G and Figure VE in 
the online-only Data Supplement) was also reversed by 
DC101 treatment. Neither VEGF-B or DC101 induced 
expression of transcripts associated with pathological 
hypertrophy in the heart (Figure VF in the online-only 
Figure 3. VEGF-B–induced cardiac hypertrophy and vascular growth are 
inhibited by blocking VEGFR2 signaling.  
A and B, Heart weight normalized to body weight (HW/BW; in mg/g) and 
cardiomyocyte (CMC) size (in µm2) in mice injected with AAV-VEGF-B186 or 
AAV-Ctrl and treated for 2 weeks with VEGFR2-blocking antibody DC101. In 
A and B, DC101 was started at the same time as the AAV injections (blocking 
experiment), and in C, 2 weeks after AAV administration, after hypertrophy 
had developed (rescue experiment; shown as gray and white bars). These 2 
groups were analyzed 2 weeks after AAV and before DC101 treatment was 
started. D through F, Quantification of blood vessel area, density, and average 
vessel diameter (blocking experiment). G, Quantification of cardiac mRNAs 
(normalized to Hprt-1). Data are mean±SEM. AAV indicates adeno-associated 
viral vector; AAV9, AAV serotype 9; Ctrl, control; mB186 and mVEGFB186, 
mouse VEGF B-186; NRP1, neuropilin 1; PECAM1, platelet and endothelial cell 
adhesion molecule 1; PLGF, placental growth factor; VEGF-B, vascular endo-
thelial growth factor B; VEGFR2, vascular endothelial growth factor receptor 
2; and WT, wild type. Two-way ANOVA (Holm-Sidak test); *P<0.05, **P<0.01, 
***P<0.001 (N= 5 per group).
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Data Supplement). AAV-PlGF–induced expansion of 
the coronary vasculature and CMC hypertrophy were 
also inhibited by DC101 (Figure VIA through VIE in the 
online-only Data Supplement). Collectively, the data 
from VEGFR1 deletion and VEGFR2 signaling inhibition 
experiments indicate that VEGFR2 activation mediates 
CMC growth even in the absence of VEGFR1.
VEGFR2 Regulates EC-CMC Cross Talk
To assess whether the effects of VEGF-B and PlGF on 
CMCs are mediated by EC-CMC cross talk or by direct 
activation of VEGFRs in the CMCs, we first analyzed 
the expression of VEGFRs and their coreceptor, neuro-
pilin-1, in human cardiac cells. VEGFR1 was abundantly 
expressed in human cardiac microvascular and arterial 
ECs, and VEGFR2 was mainly expressed in microvascu-
lar ECs (Figure 4A through 4C). In contrast, very little if 
any VEGFR RNA expression was observed in the CMCs 
or fibroblasts, whereas neuropilin-1 was abundantly ex-
pressed in all cell types.
To provide additional evidence that endothelial 
VEGFR2 signaling mediates CMC growth in a paracrine 
manner, we treated Cdh5-CreERT2;VEGFR2fl/fl mice with 
tamoxifen to delete VEGFR2 specifically in the ECs of 
adult mice (R2EC∆/∆ mice; Figure 4D and 4E). AAV-VEGF-
B and AAV-PlGF were injected into these mice 1 week 
after VEGFR2 gene deletion. Similar to the DC101 an-
tibody treatment, deletion of VEGFR2 from ECs com-
pletely prevented the VEGF-B–induced (Figure 4F and 
4G) and PlGF-induced (Figure 4H and 4I) cardiac phe-
notypes. Deletion of VEGFR1 in CMCs using conditional 
Myh6-CreERT2 or constitutive αMHC-Cre deleter mice 
did not alter the cardiac phenotype, in marked contrast 
to the deletion of VEGFR1 in the ECs (Figure VIIA and 
VIIB in the online-only Data Supplement). Collectively, 
these data are consistent with the observation that 
CMCs express little or no VEGFR1 (Figure 4A and 4B), 
and they support the hypothesis that VEGFR2 activation 
in ECs promotes CMC growth. Thus, these data provide 
multiple lines of evidence in support of the concept that 
angiogenesis-induced cardiac hypertrophy is mediated 
by EC-CMC cross talk. Specifically, these data show 
that VEGFR1 deletion from the ECs, or its occupancy by 
VEGF-B or PlGF, induces expansion of the coronary vas-
culature and concomitant CMC growth via increased 
VEGF-VEGFR2 signaling in ECs.
Paracrine Signaling From ECs to CMCs
VEGFR2 activation has been shown to increase the pro-
duction of angiocrine factors from ECs to support pa-
renchymal cell regeneration and growth on injury, for 
example, in the lung or liver.14–16,26 To identify possible 
angiocrines responsible for CMC growth, we compared 
the profiles of transcripts encoding secreted proteins 
in the hearts of VEGFR1-deleted, AAV-VEGF-B–ex-
pressing, and control mice. Transcripts encoding a se-
cretion signal peptide that were significantly upregu-
lated by both treatments and their combination were 
selected for further analysis. Furthermore, we focused 
only on the transcripts for which increased expression 
after AAV-VEGF-B injection was inhibited by DC101. 
Such transcripts included Adam12, Apelin/APJ, Hbegf, 
Tgfb1, Stc1, Egfl7, Gdf10, Timp3, Angpt2, Esm1, and 
Klk8 (quantitative polymerase chain reaction data pre-
sented in Figure 2B and in Figure VE in the online-only 
Data Supplement).
Interaction Between VEGFR2 and ErbB 
Pathways
First, we tested the possible role of apelin and its re-
ceptor APJ in VEGF-B–induced hypertrophy by injecting 
AAV-VEGF-B into mice deficient in the apelin recep-
tor APJ.27 VEGF-B induced similar vascular and cardiac 
growth in both WT and APJ knockout mice, which sug-
gests that apelin/APJ signaling does not mediate EC-
induced CMC growth (Figure VIIIA through VIIID in the 
online-only Data Supplement).
Next, we focused on Adam12, Hbegf, and Klk8, 
which all have been linked to ErbB signaling. ErbB 
receptors and their ligands have been shown to be 
important for heart development, homeostasis, and 
regeneration.13,28–30 Adam12 is a protease involved in 
the shedding of proteins of the epidermal growth fac-
tor (EGF) family (eg, HB-EGF [heparin-binding EGF–like 
growth factor]) from the cell surface,31 which then can 
bind and activate ErbB receptors on CMCs and induce 
cardiac growth.30,32 Klk8 (also known as neuropsin), in 
turn, has been shown to cleave Nrg1 from cell surface, 
resulting in ErbB4 activation in the brain.33 The upregu-
lation of Adam12, Hbegf, and Klk8 by VEGF-B expres-
sion or VEGFR1 deletion suggested that ErbB signaling 
is responsible for the CMC activation and hypertro-
phy. Importantly, these changes were fully inhibited by 
DC101, which indicates that they are downstream of 
VEGFR2 activation.
To study the interaction between the VEGF and ErbB 
receptor pathways, human ECs were treated with VEGF. 
This treatment led to significantly increased Hbegf mRNA 
levels in human cardiac arterial and microvascular ECs 
and dermal microvascular ECs (Figure 5A through 5D). 
In addition, expression of the short form of Adam12 
was upregulated after VEGF treatment of human car-
diac arterial ECs and human umbilical vein ECs. VEGF 
treatment of ECs induced the release of Nrg1 into cell 
culture medium (Figure 5E and Figure IXA and IXB in the 
online-only Data Supplement), and incubation of CMCs 
with the conditioned medium from VEGF-treated ECs 
resulted in increased phosphorylation of Akt, a signal-
ing kinase that promotes myocyte growth,7 at Ser473 
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(Figure IXC in the online-only Data Supplement). Fur-
thermore, activation of Akt was inhibited by addition 
of Nrg1 blocking antibody to the culture medium (Fig-
ure 5F). These data show that VEGF induces Hbegf and 
Adam12 production and promotes Nrg1 release from 
the ECs. Because Nrg1 activates Akt, these data support 
the hypothesis that ErbB can mediate EC-CMC cross talk 
(Figure IXD in the online-only Data Supplement).
Figure 4. Endothelial VEGFR2 deletion inhibits VEGF-B–induced cardiomyocyte hypertrophy.  
A through C, Relative VEGFR1, VEGFR2, and NRP1 mRNA expression levels in human coronary microvascular endothelial cells (HCMEC), human coronary arterial endo-
thelial cells (HCAEC), human cardiomyocytes (HCM), and human cardiac fibroblasts (HCF). D and E, VEGFR2 protein levels in R2EC∆/∆ mouse hearts analyzed by Western 
blot and immunohistochemistry. Heart to body weight ratio (HW/BW; in mg/g) and blood vessel area (%) are shown in AAV-VEGF-B186 (F and G) and in AAV-PlGF–
treated wild-type and R2EC∆/∆ mice (H and I). Data are mean±SEM. AAV indicates adeno-associated viral vector; HSC70, heat shock cognate 70; mB186, mouse VEGF 
B-186; mPlGF2, mouse placental growth factor 2; NRP1, neuropilin 1; VEGF-B, vascular endothelial growth factor B; VEGFR1 and VEGFR2, vascular endothelial growth 
factor receptor 1 and 2; and WT, wild type. Two-way ANOVA (Holm-Sidak test); *P<0.05, **P<0.01, ***P<0.001 (N= 3 per group). Scale bars, 100 µm.
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Next, we designed an AAV vector encoding the ex-
tracellular ligand-binding domain of the ErbB4 recep-
tor fused with the immunoglobulin gamma Fc domain 
(AAV-ErbB4ECD) to trap ErbB ligands in serum and in 
tissues. WT mice were injected with AAV-VEGF-B to-
gether with AAV-ErbB4ECD or a control vector. AAV-
VEGF-B treatment induced phosphorylation of EGF re-
ceptor and ErbB4 in the heart, and this was attenuated 
in mice that also received AAV-ErbB4ECD (Figure  6A 
and 6D through 6F). No effect on the phosphorylation 
of ErbB3 was observed. HB-EGF protein levels were 
increased in VEGF-B–expressing hearts, whereas there 
was no effect on total cardiac Nrg1 or Nrg4 expression 
(Figure 6B, 6C, 6G, and 6H). However, ErbB4ECD did 
not alter VEGF-B–induced angiogenesis, which indi-
cates that it only affected signals downstream of VEG-
FR2 and angiogenesis (Figure XA and XB in the online-
only Data Supplement).
In another experiment, mice were also treated with 
the EGF receptor/ErbB TK inhibitor afatinib together 
with AAV-VEGF-B, and the expression of signaling mol-
ecules downstream of ErbB was analyzed. The VEGF-B–
induced increase in cardiac hypertrophy–associated 
transcripts, encoding PI3K-p110β, Akt, Carp/Ankrd1, 
and Tbx3, was blocked, and the VEGF-B–induced de-
crease of C/EBPβ (CCAAT/enhancer binding protein 
beta) mRNA was restored by afatinib (Figure  7A). 
Treatment with DC101 to block VEGFR2 signaling had 
similar effects (Figure 7B). Importantly, afatinib did not 
affect the VEGF-B–induced increase of VEGFR2 expres-
sion (Figure 7A); thus, its effects were mediated at the 
level of downstream signaling. Afatinib blocked the 
VEGF-B–induced phosphorylation of Akt and Erk, and 
there was a trend toward decreased S6 kinase phos-
phorylation (Figure 7C and 7D). Notably, downregula-
tion of C/EBPβ is consistent with activation of physi-
ological heart growth.34 Although both AAV-ErbB4ECD 
and afatinib inhibited the hypertrophy-associated bio-
chemical signals induced by VEGF-B in the heart, their 
effects on the VEGF-B–induced increase in cardiac mass 
did not reach statistical significance (Figure XC through 
XH in the online-only Data Supplement).
AAV-VEGF-B Does Not Induce 
Pathological Cardiac Hypertrophy
To evaluate the long-term effects of hypertrophy in 
VEGFR1-deleted and VEGF-B–overexpressing mice, we 
analyzed cardiac function by echocardiography in adult 
mice 3 weeks, 2.5 months, and 5 months after tamoxi-
fen administration and AAV-VEGF-B treatment. Despite 
mild cardiac hypertrophy, cardiac function was not sig-
nificantly altered (Figure XIA and Table IV in the online-
only Data Supplement), and there was no change in 
pathological marker gene expression or in maximal 
exercise capacity in these mice 5 months after the 
treatments (Figure XIB and XIC in the online-only Data 
Supplement). Significantly lower blood pressure was 
observed in both the VEGFR1-deficient and VEGF-B–
overexpressing mice and their combination (Figure XID 
in the online-only Data Supplement).
DISCUSSION
ECs are emerging as important signaling centers that 
regulate growth, regeneration, and differentiation of 
their surrounding cells and tissues. Paracrine (angioc-
Figure 5. VEGF stimulation induces HB-EGF and ADAM12 mRNA expres-
sion and Nrg1 release in endothelial cells.  
A through D, Human cardiac arterial (HCEAC), cardiac microvascular 
(HCMEC), dermal microvascular (HDMEC), and umbilical vein endothelial 
cells (HUVEC) were stimulated with vascular endothelial growth factor 
(VEGF; 100 ng/mL) for 4 hours, and mRNA expression was analyzed. E, 
Nrg1 levels in conditioned medium from HCMECs stimulated with VEGF. F, 
Phosphorylation of Akt in cardiomyocytes (CMC) treated with conditioned 
medium (CM) from HCMECs stimulated with VEGF. Note that Akt activation 
is blocked with the anti-Nrg1 antibody. HB-EGF indicates heparin-binding 
epidermal growth factor–like growth factor; Ig, immunoglobulin; and Nrg1, 
neuregulin 1. Student t test (A through D) and 1-way ANOVA (E); **P<0.01, 
***P<0.001 (N=3 per group).
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rine) release of molecules from ECs has recently been 
shown to be fundamentally important for such cross 
talk in other tissues.35,36 The present findings shed light 
on the mechanism of how angiogenesis induces physi-
ological CMC growth and highlight the importance of 
EC-CMC cross talk in cardiac homeostasis. We show 
that activation of endothelial VEGFR2 signaling in the 
heart induces vascular growth and contributes to CMC 
hypertrophy by inducing release of ErbB ligands from 
ECs, which then act on the CMCs. We propose that 
angiogenesis-induced hypertrophy exhibits features 
of physiological hypertrophy, because there was no 
change in cardiac function, exercise capacity, or the 
expression of pathological marker transcripts in mice 
treated with AAV-VEGF-B or in VEGFR1-deleted mice, 
similar to what we have shown previously in VEGF-B 
transgenic rats.10 We suspect that this is attributable 
to the balanced growth of the vasculature and CMCs, 
whereas in pathological hypertrophy and subsequent 
heart failure, there is a mismatch that is caused by vas-
cular rarefaction.6 Importantly, both VEGFR1 deletion 
and AAV-VEGF-B overexpression and their combination 
decreased blood pressure, which indicates that the ef-
fects on cardiac hypertrophy cannot be attributed to 
increased blood pressure.
VEGF-B and PlGF bind exclusively to VEGFR1, which 
is considered to act mainly as a decoy receptor that 
functions to adjust the levels of VEGF, the predomi-
nant angiogenic factor, to a physiologically appropriate 
range.37,38 Recent data also indicate that VEGFR1 is re-
quired for the spatial regulation of vascular growth by 
controlling the formation of anastomoses of vascular 
sprouts.23 The proposed decoy function of VEGFR1 is 
supported by our observations that both the deletion 
of VEGFR1 and the overexpression of its ligands VEGF-
B and PlGF produced similar effects on vascular growth 
and CMC hypertrophy in the heart. Further support for 
this model comes from the finding that deletion of the 
Figure 6. Analysis of ErbB ligands and receptors in the AAV-VEGF-B186 and AAV-ErbB4-ECD–treated mouse heart.  
A through I, Representative Western blots and quantification of phosphorylation of ErbB receptors normalized to total receptors and expression of HB-EGF, 
Nrg1, and Nrg4 normalized to β-actin (as fold change, Ctrl=1). For epidermal growth factor receptor (EGFR), the lower 175-kDa band was quantified. Numbers 
per group: pEGFR, n=4–6; pErbB3, n=7–8; pErbB4, n=3–4; HB-EGF, n=5; and Nrg1 and Nrg 4, n=10–15. AAV indicates adeno-associated viral vector; HB-EGF, 
heparin-binding epidermal growth factor–like growth factor; mB186, mouse VEGF B-186; Nrg1, neuregulin 1; Nrg4, neuregulin 4; pEGFR, phosphorylated epi-
dermal growth factor receptor; and pErbB3 and pErbB4, phosphorylated ErbB3 and ErbB4. Shapiro-Wilk normality test and Mann–Whitney multiple comparison 
test; *P<0.05, **P<0.01.
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Figure 7. VEGF-B–induced changes in signaling molecules related to cardiac hypertrophy are inhibited by both VEGFR2 and ErbB blocking.  
A and B, VEGF-B–induced increased transcript expression of PI3K-p110β, Akt, Carp/Ankrd1, and Tbx3 and decreased expression of C/EBPβ in the heart were 
blocked by both DC101 and afatinib treatment. C through F, Afatinib restored the VEGF-B–induced phosphorylation of Akt and Erk, with a similar trend for S6 
kinase (S6K). Data are mean±SEM. AAV9 indicates adeno-associated viral vector serotype 9; Ctrl, control; mB186, mouse VEGF B-186; pErk1/2, phosphorylated 
Erk1/2; PI3K, phosphoinositide 3-kinase; pS6K, phosphorylated S6 kinase; and VEGF-B, vascular endothelial growth factor B. Two-way ANOVA (Holm-Sidak test); 
*P<0.05, **P<0.01 (N=4–5 per group).
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TK domain of VEGFR1 was not essential for VEGF-B–
induced vascular or cardiac growth. Although our 
previous studies indicated that constitutive loss of the 
VEGFR1 TK domain is required for cardiac hypertrophy 
induced by the VEGF-B167 isoform during mouse de-
velopment, the present results indicate that TK activity 
is not essential for VEGF-B–induced cardiac growth in 
adult mice. Interestingly, we found that both VEGFR1-
deficient and TK−/− hearts had increased VEGFR2 levels 
and that silencing of VEGFR1 in cultured ECs increased 
VEGFR2 expression. Increased VEGFR2 expression has 
also been observed recently in ECs of VEGFR3-deleted 
mice,39 which indicates the EC-intrinsic regulation of 
VEGFRs. Changes in the global gene expression profiles 
were highly similar in VEGFR1-deficient and VEGF-B–
overexpressing hearts, which demonstrates that both 
manipulations affected similar angiogenic pathways. 
Our findings are also consistent with those of Ho et 
al,40 who showed that global deletion of VEGFR1 using 
the Rosa26-CreERT2 transgene increases vasculature and 
VEGFR2 levels in the heart, although possible effects on 
CMCs or cardiac growth were not reported.
Because we did not find evidence that intracellular 
VEGFR1 signaling is required for the coronary vascu-
lar expansion or cardiac hypertrophy induced by its li-
gands, we focused on the role of VEGFR2 in EC-CMC 
cross talk. Our results showed that both VEGFR1 and 
VEGFR2 were almost exclusively expressed in cardiac 
ECs, whereas very little, if any, expression was detected 
in CMCs and cardiac fibroblasts. A recent study using 
VEGFR1 (Flt1) and VEGFR2 (Flk1) reporter mice dem-
onstrated that VEGFR1 is homogenously expressed in 
ECs throughout the heart, whereas VEGFR2 showed 
an epicardial-to-endocardial gradient and was down-
regulated in quiescent large coronary vessels in adult 
mice,41 as also indicated by our previous findings.10 Us-
ing the VEGFR2-blocking antibody DC101, we showed 
here that the cardiac hypertrophy induced by VEGF-B 
or PlGF can be prevented and, importantly, reversed by 
this inhibition of VEGFR2 signaling. Conditional dele-
tion of VEGFR2 in the vascular endothelium of adult 
mice provided additional evidence that endothelial 
VEGFR2 activation is required for vascular expansion 
and VEGF-B– and PlGF-induced hypertrophy. Although 
VEGF is known to cause vascular leakage, even when 
VEGF-B was overexpressed in VEGFR1-deficient mice, 
we observed only a modest increase in leakage that 
was several-fold less than what is observed with VEGF 
treatment. Thus, our combined results suggest that 
VEGFR1 and its specific ligands fine-tune endogenous 
VEGF-VEGFR2 signaling in the heart. The resulting 
physiological vascular growth induces mild CMC hy-
pertrophy (20%–30%) within 1 to 2 weeks, without 
progression to heart failure.
What are the signals from VEGF-B–stimulated ECs 
that promote CMC growth? Using whole-genome mi-
croarray analyses, we identified upregulated endothelial 
transcripts that encode a signal peptide for secretion of 
their protein products. Of the potential candidates, we 
first tested the role of the apelin/APJ pathway, which 
has been suggested to regulate pathological heart 
growth.17 However, we found no difference in AAV-
VEGF-B–induced cardiac hypertrophy between WT and 
APJ-deficient mice. Genetic loss of APJ has been shown 
to confer resistance to pressure overload–induced myo-
cardial hypertrophy,42 but our results indicated that APJ 
does not mediate angiogenesis-induced hypertrophy 
under these experimental conditions.
VEGFR2 activation markedly increased the expres-
sion of Adam12 metalloprotease both in vivo and in 
cultured ECs, and this effect was fully inhibited by the 
DC101 antibody treatment. Adam12 is known to shed 
HB-EGF from ECs,31 allowing HB-EGF to bind to and 
activate ErbB receptors on CMCs to induce myocardial 
hypertrophy.32 HB-EGF belongs to the EGF family, which 
also includes neuregulins. Nrg1 and ErbB2 and ErbB4 
receptors are essential for cardiac development, and 
they play a critical role in both healthy and diseased 
adult heart.28–30 HB-EGF–induced activation of ErbB re-
ceptors has been shown to be crucial for normal heart 
development and function.43,44 AAV-VEGF-B increased 
the amount of HB-EGF in the heart and induced phos-
phorylation of EGF and ErbB4 receptors. Furthermore, 
cell culture studies showed that VEGF stimulation in-
creased the release of Nrg1 from cardiac ECs, and the 
conditioned medium from ECs induced phosphoryla-
tion of Akt in CMCs, which could be blocked by Nrg1 
antibodies added to the medium.
A previous report demonstrated that Nrg1 activates 
mTORC1 (mammalian target of rapamycin complex 1) 
and Akt in cultured CMCs via ErbB2/ErbB4, which was 
accompanied by increased glucose uptake and protein 
synthesis.45 These observations paralleled our previous 
findings, which demonstrated activation of Akt and 
mTORC1 and increased glucose uptake in VEGF-B trans-
genic rat hearts.10 Furthermore, we demonstrated that 
the AAV-VEGF-B–induced increase in hypertrophy-asso-
ciated transcripts was restored by blocking the VEGFR2 
or ErbB signals. In addition, both DC101 and afatinib in-
hibited the VEGF-B–induced downregulation of C/EBPβ, 
which has been shown to be important for the develop-
ment of physiological hypertrophy.34 Collectively, these 
findings implicate pathways associated with physiologi-
cal hypertrophy downstream of angiocrine signaling.
Cardiac overexpression of the extracellular ligand-
binding domain of ErbB4, an inhibitory ligand trap, had 
no effect on VEGF-B–induced angiogenesis but attenu-
ated the phosphorylation of EGF receptor and ErbB4 
and had a limited impact on VEGF-B–induced cardiac 
hypertrophy. Together, the results from cell culture and 
animal experiments suggest that VEGFR2 activation in 
ECs leads to ErbB ligand shedding from the ECs and 
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stimulation of their receptor(s) in CMCs. Although this 
may be one of the links between angiogenesis and CMC 
activation and growth, it is likely that other signals that 
are not inhibited by the blocking of ErbB signaling also 
contribute to the cross talk between ECs and CMCs. 
For example, NO has been suggested to mediate PlGF-
induced hypertrophy, because chemical or genetic in-
hibition of endothelial NO synthase partially prevented 
cardiac growth.8,9 Because NO production is increased 
by VEGFR2 activation, it is possible that increased NO 
availability and Notch-ErbB pathways downstream of 
VEGFR2 cooperate to control CMC growth.
The mechanism proposed herein is also supported 
by studies in other cell types. For example, VEGFR and 
Notch signaling pathways are well known to interact 
in both ECs and neural cells.46 In cancer cells and fi-
broblasts, Notch has been demonstrated to increase 
the expression of Adam1247 and to induce HB-EGF 
shedding by Adam12.31 Furthermore, in the develop-
ing heart endocardium, Notch increases Hbegf expres-
sion, which acts as a paracrine signal for the neighbor-
ing myocardium.48 These data collectively support our 
model, which connects activation of VEGFR2/Notch to 
increased expression of Adam12 and the release of HB-
EGF. One of the genes that was induced by VEGF-B and 
blocked by DC101 was Klk8 (kallikrein-8/neuropsin). 
In the hippocampus, Klk8 is required for Nrg1 cleav-
age and ErbB4 activation,33 and transgenic overexpres-
sion of Klk8 has been shown to induce cardiac hyper-
trophy.49 Thus, the present results suggest that VEGF, 
VEGF-B, or PlGF secreted by CMCs activate VEGFR2 in 
cardiac ECs, and this will induce Notch signaling and 
upregulation of Id1, EphrinB2, Hbegf, Adam12, and 
Klk8 in ECs. In turn, this leads to the release of ErbB 
ligands from the ECs, which can then activate ErbB re-
ceptors in CMCs. Importantly, inhibition of endothelial 
VEGFR2, either with antibodies or by genetic ablation, 
fully blocked these downstream effects. This model is 
illustrated in Figure 8. Notably, the 2 EGF family ligands, 
HB-EGF and Nrg1, have distinct receptor binding and 
expression profiles, and thus, they likely have distinct 
functions in EC-CMC paracrine cross talk.
The present results also demonstrate that angiogen-
esis-induced hypertrophy is physiological, even during 
prolonged periods of time. AAV-VEGF-B–transduced or 
VEGFR1-deleted hearts did not show signs of patholog-
ical hypertrophy or heart failure, which extends the re-
sults we previously obtained in VEGF-B transgenic rats.10 
This is likely because of the coordinated growth of both 
the vasculature and the CMCs by these manipulations. 
Reversibility is a key hallmark of the physiological hyper-
trophy induced by exercise or pregnancy. Importantly, 
by blocking angiogenesis with VEGFR2 antibody, we 
were able to reverse the AAV-VEGF-B–induced hyper-
trophy. The present results suggest that vascular growth 
could be the main trigger of physiological hypertrophy, 
which makes it fundamentally different from the devel-
opment of pathological hypertrophy, in which angio-
Figure 8. Schematic illustrating endothelial cell to cardiomyocyte cross talk in angiogenesis-induced cardiomyocyte hypertrophy.  
Adeno-associated viral vector serotype 9 (AAV9) encoding vascular endothelial growth factor B (VEGF-B) or placental growth factor (PlGF) transduces the cardiomy-
ocytes. The secreted VEGF-B and PlGF bind to vascular endothelial growth factor receptor 1 (VEGFR1) in the endothelial cells and increase the bioavailability of en-
dogenous vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2). Activation of VEGFR2 in endothelial cells induces the activation of Dll4/NOTCH 
signaling, which leads to coronary angiogenesis and arteriogenesis. In addition, endothelial cell VEGFR2 activation upregulates the expression of Id1, apelin, APJ, 
ESM1, EfnB2, Klk8, and Adam12. Adam12 and Klk8–mediated shedding of heparin-binding epidermal growth factor–like growth factor (HB-EGF) and neuregulin 
1 (Nrg1) from the endothelial cell surface produces soluble cleaved forms of these proteins. HB-EGF and Nrg1 bind and activate epidermal growth factor receptor 
1 (EGFR1 [ErbB1]) and ErbB4 in cardiomyocytes and promote cardiomyocyte growth.
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genesis occurs as a compensatory mechanism induced 
by increased myocardial mass and cardiac hypoxia.
In conclusion, using various genetic and pharma-
cological animal models and cell culture experiments, 
we demonstrate that angiogenesis-induced myocar-
dial hypertrophy is mediated via activated VEGFR2 and 
Notch pathways in ECs, which can induce the release 
of ligands activating ErbB receptors present in CMCs. 
The present results further our understanding of the 
differences between physiological and pathological 
hypertrophy and highlight the importance of EC-CMC 
cross talk by identifying a new mechanism for how ECs 
control the physiological growth of CMCs.
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